Nimotuzumab plus tislelizumab for recurrent cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) plus radiation for women whose cervical cancer has come back or spread to a few places in the body. The goal is to see if this treatment can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your cervical cancer has come back or spread to other parts of the body (recurrent or metastatic)
- You have a limited number of tumors (5 or fewer total, in 3 or fewer organs) and your doctor plans to treat them with radiation
- You have not had previous treatments like anti-EGFR or anti-PD-1/PD-L1 therapy (e.g., cetuximab, pembrolizumab)
- You have not had another cancer in the last 5 years (except some skin cancers or thyroid cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the drug nimotuzumab to standard chemoradiotherapy (radiation plus chemo) and then continuing maintenance therapy works better for locally advanced cervical cancer (stages IB3 to IVA) than chemoradiotherapy alone.
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests combining two drugs (nituzumab and serplulimab) with focused radiation to treat cervical cancer that has not responded to other therapies. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.